K Pharma (4896) · RiskRestated
Risk of changes to the use of proceeds and allocation weighting for a public offering of new shares and other transactions
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of Changes in the Use and Allocation of Funds Raised through Public Offerings and Other MeansA theme 16 companies write about · 7 as a headwind · 5 as a tailwind
The whole theme swung hardest in 2026: 2 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「The use and allocation of these funds may change because of changes in the business environment, market trends or unforeseen business factors.」
The company reiterates the risk that the use and allocation of funds raised through public offerings and bond issues may change. - FY2024First statedAnnual report
「The use and allocation of these funds may change because of changes in the business environment, market trends or unforeseen business factors.」
The company first separately disclosed the risk that the planned use and allocation of public-offering proceeds for research and development, the U.S. research institute and working capital could change because of business-environment or other factors.